Published in Vaccine Weekly, August 3rd, 2005
Based on a thorough review of the first phase IIb trial (Study 916) results, the investigators confirmed their interest in extending the treatment period of the ongoing second phase IIb trial employing a higher dose of E1 (Study 918). With a total duration of 3 years, final results of the second phase IIb trial are now expected to be announced in the second half of 2007.
On June 1, Innogenetics announced the results...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly